

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6127)

2024 FIRST QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the first quarterly report of JOINN Laboratories (China) Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) for financial year 2024 (the “**2024 First Quarterly Report**”). This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By Order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson

Beijing, the PRC, 29 April 2024

As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.

IMPORTANT NOTICE

The board of Directors, the Supervisory Committee, the Directors, Supervisors and senior management of the Company warrant that the information stated in this quarterly report is true, accurate, complete and without any false representation, misleading statement or material omission, and assume several and joint liabilities.

The person in charge of the Company, the person in charge of accounting affairs, and the person responsible for the accounting department (head of the accounting department), hereby warrant the truthfulness, accuracy and completeness of the financial statements contained in this quarterly report.

Whether the first quarterly report has been audited

Yes No

I. MAJOR FINANCIAL DATA

(I) Key accounting data and financial indicators

Unit: RMB Currency: RMB

Item	Reporting Period	Change during the Reporting Period compared to the same period of last year (%)
Revenue	324,809,103.67	-12.07
Net profit attributable to shareholders of the Company	-272,222,474.99	-244.98
Net profit attributable to shareholders of the Company after deducting non-recurring gain or loss items	-280,666,741.34	-251.92
Net cash flow from operating activities	119,953,519.31	N/A
Basic earnings per share (RMB per share)	-0.36	-244.00
Diluted earnings per share (RMB per share)	-0.36	-244.00
Weighted average return on net assets (%)	-3.35	Decreased by 5.62 percentage points

	At the end of the Reporting Period	At the end of last year	Change as compared to the end of last year (%)
Total assets	9,733,254,487.30	10,027,159,630.47	-2.93
Owners' equity attributable to shareholders of the listed company	7,993,144,600.58	8,279,315,724.35	-3.46

Description of key accounting data and financial indicators of the Company for the end of this quarter:

1. Factors affecting the net profit attributable to shareholders of listed company after deducting non-recurring gain or loss items

The net profit attributable to shareholders of the listed company after deducting non-recurring gain or loss items is primarily affected by the fluctuation in market prices of biological assets and the loss incurred in the laboratory services business, as well as the fund management income.

- 1) The change in fair value of biological assets incurred a net loss of RMB284,048,900 during the Reporting Period.
- 2) The laboratory services business incurred a net profit of RMB-21,043,700 during the Reporting Period, representing a year-on-year decrease of 130.01% (corresponding period of last year: RMB70,116,300), which was mainly attributable to intensified competition and decline in gross profit margin.
- 3) The fund management income generated a net profit of RMB24,425,800 during the Reporting Period.

2. Changes in the non-recurring profit or loss

The non-recurring profit or loss for the Reporting Period was RMB8,444,300. The non-recurring profit or loss items and their respective amount are detailed in the following disclosures.

Note: Net profit generated from the laboratory services business: Net profit attributable to shareholders of the listed company after deducting non-recurring gain or loss items, eliminating the impact of gain or loss from change in fair value of biological assets and interest income and foreign exchange gain or loss.

(II) Non-recurring profit or loss items and amounts✓ Applicable Not applicable

Unit: RMB Currency: RMB

Non-recurring profit or loss items	Amount for the period	Description
Gain or loss on disposal of non-current assets (including the write-off portion of the provision for asset impairment recognized)	-39,103.58	
Government grants included in profit or loss of the current period, except for those closely related to the Company's normal operation, granted in accordance with national policies and prescribed standards and affecting the Company's profit or loss account on an ongoing basis	5,949,201.29	
Profit or loss arising from changes in the fair value of financial assets and financial liabilities held by non-financial enterprises and profit or loss arising from disposal of financial assets and financial liabilities, except for effective hedging business related to normal operating of the Company	4,597,688.10	
Capital occupancy fee from non-financial enterprises recognized through profit or loss for the period		
Gain or loss from entrusted investments or assets management		
Profit or loss from external entrusted loans		
Asset losses caused by force majeure (such as natural disasters)		
Reversal of provision for impairment of receivables subject to impairment test separately		
Gain from the difference between the cost of investment on the subsidiaries, associates and joint ventures and the shared fair value of identifiable net assets of the investee		
Net profit or loss of subsidiaries resulting from merger of enterprises under common control from the beginning of the current period to the date of merger		
Profit or loss from exchange of non-monetary assets		
Profit or loss from debt restructuring		

Non-recurring profit or loss items	Amount for the period	Description
One-off expenses incurred due to discontinuation of relevant operation activities (such as staff resettlement expenses)		
One-off effect on profit or loss of the current period due to adjustments of taxation and accounting laws and regulations		
Share-based payment expenses recognized on the one-off basis due to cancellation or revision of the equity incentive plan		
Profit or loss from changes in the fair value of employee benefit payables after the vesting date (in respect of share-based payment settled by cash)		
Profit or loss from changes in fair value of investment properties using the fair value model for subsequent measurement		
Gain from the transaction at an unfair price		
Profit or loss from contingencies not related to the ordinary operations of the Company		
Fees income from custodian business		
Other non-operating incomes and expenses other than the above items	-82,637.33	
Other profit or loss items falling within the meaning of non-recurring profit or loss	-558,720.76	
Less: Effect of income tax	1,422,161.37	
Effect on interest of minority shareholders (after tax)		
Total	8,444,266.35	

Information on the designation of items not listed in “Explanatory Announcement No. 1 on Disclosure of Information by Companies with Publicly Issued Securities – Non-recurring Profit or Loss” as non-recurring profit or loss items of significant amount and the classification of non-recurring profit or loss items listed in “Explanatory Announcement No. 1 on Disclosure of Information by Companies with Publicly Issued Securities – Non-recurring Profit or Loss” as recurring profit or loss items, with relevant reasons provided.

Applicable Not applicable

(III) Changes in key accounting data and financial indicators and reasons for such changes

Applicable Not applicable

Items	Change (%)	Main reason
Net profit attributable to shareholders of the listed company	-244.98	Mainly due to the decrease in net profit from the laboratory services business and the loss from the change in fair value of biological assets in the Reporting Period
Net profit attributable to shareholders of the listed company after deducting of non-recurring profit or loss	-251.92	
Basic earnings per share (RMB per share)	-244.00	
Diluted earnings per share (RMB per share)	-244.00	
Weighted average return on net assets (%)	Decreased by 5.62 percentage points	
Net cash flow from operating activities	N/A	Mainly due to the decrease in payment for research models in the Reporting Period

II. INFORMATION OF SHAREHOLDERS

(I) Statement of the total number of holders of ordinary shares and holders of preference shares with restored voting rights, and the particulars of shareholdings of the top 10 shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the Reporting Period	74,233	Total number of holders of preference shares with restored voting rights as at the end of the Reporting Period (if any)	0			
Shareholding of top 10 shareholders (excluding shares lent under the refinancing and securities lending arrangement)						
Name of shareholder	Nature of shareholder	Number of shares held	Percentage of shareholding (%)	Number of Shares subject to trading restrictions	Shares pledged, marked or frozen	
					Status of shares	Number of shares
Feng Yuxia	Domestic natural person	167,160,633	22.29	0	Nil	
HKSCC NOMINEES LIMITED	Overseas legal person	118,973,414	15.87	0	Nil	
Zhou Zhiwen	Domestic natural person	74,725,981	9.96	0	Nil	
Gu Xiaolei	Domestic natural person	21,420,504	2.86	0	Pledged	9,604,000
National Social Security Fund (Combination 406)	Others	16,319,096	2.18	0	Nil	
Zuo Conglin	Domestic natural person	14,098,317	1.88	0	Nil	
Gu Meifang	Domestic natural person	10,322,035	1.38	0	Pledged	8,400,000
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	Others	10,313,964	1.38	0	Nil	
Hong Kong Securities Clearing Company Limited	Overseas legal person	8,375,502	1.12	0	Nil	
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	Others	7,352,129	0.98	0	Nil	

Shareholdings of top 10 holders of shares not subject to trading restrictions			
Name of shareholder	Number of shares not subject to trading restrictions	Class and number of shares	
		Class of shares	Number of shares
Feng Yuxia	167,160,633	RMB-denominated ordinary shares	167,160,633
HKSCC NOMINEES LIMITED	118,973,414	Overseas-listed foreign shares	118,973,414
Zhou Zhiwen	74,725,981	RMB-denominated ordinary shares	74,725,981
Gu Xiaolei	21,420,504	RMB-denominated ordinary shares	21,420,504
National Social Security Fund (Combination 406)	16,319,096	RMB-denominated ordinary shares	16,319,096
Zuo Conglin	14,098,317	RMB-denominated ordinary shares	14,098,317
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	10,730,664	RMB-denominated ordinary shares	10,730,664
Gu Meifang	10,322,035	RMB-denominated ordinary shares	10,322,035
Hong Kong Securities Clearing Company Limited	8,375,502	RMB-denominated ordinary shares	8,375,502
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	7,494,929	RMB-denominated ordinary shares	7,494,929
Description of related party relationships or concerted actions of the above shareholders	1. Feng Yuxia and Zhou Zhiwen are in a spousal relationship; 2. Gu Meifang and Gu Xiaolei are aunt and nephew. Except from this, the Company is not aware of any related party relationship among the shareholders mentioned above, and not aware of whether they are parties acting in concert.		
Description of top 10 shareholders and top 10 shareholders not subject to trading restrictions participating in margin trading and refinancing business (if any)	Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund and Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund have involved in the refinancing business, whereas the other top 10 shareholders have not participated in any of such activities.		

Information of shares lent under the refinancing and securities lending arrangement in which shareholders owning over 5% equity, top 10 shareholders and top 10 shareholders not subject to trading restrictions have involved

✓ Applicable □ Not applicable

Unit: Share

Shares lent under the refinancing and securities lending arrangement in which shareholders owning over 5% equity, top 10 shareholders and top 10 shareholders not subject to trading restrictions have involved								
Full name of shareholder	Shares held under the general account and credit account at the beginning of Reporting Period		Shares lent under the refinancing arrangement but not returned at the beginning of Reporting Period		Shares held under the general account and credit account at the end of Reporting Period		Shares lent under the refinancing arrangement but not returned at the end of Reporting Period	
	Total number	Proportion (%)	Total number	Proportion (%)	Total number	Proportion (%)	Total number	Proportion (%)
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	10,850,564	1.45	494,600	0.066	10,730,664	1.43	416,700	0.056
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	7,435,989	0.99	169,100	0.023	7,494,929	1.00	142,800	0.019

Change in the Reporting Period (as compared to the same period of last year) due to the lending/return of shares under the refinancing arrangement by top 10 shareholders and top 10 shareholders not subject to trading restrictions

Applicable Not applicable

Unit: Share

Change in the Reporting Period (as compared to the same period of last year) due to the lending/return of shares under the refinancing arrangement by top 10 shareholders and top 10 shareholders not subject to trading restrictions					
Full name of shareholder	Addition/ withdrawal in the Reporting Period	Shares lent under the refinancing arrangement but not returned at the end of Reporting Period		Shares held under the general account and credit account, and lent under the refinancing arrangement but not returned at the end of Reporting Period	
		Total number	Proportion (%)	Total number	Proportion (%)
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	Withdrawal	416,700	0.056	10,730,664	1.43
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	Withdrawal	142,800	0.019	7,494,929	1.00

III. OTHER MATTERS REQUIRED ATTENTION

Other important information on the Company's operation during the Reporting Period that needs to be brought to the attention of investors

Applicable Not applicable

Owing to the combined effect of multiple factors, new orders of the Group were approximately RMB400 million for the Reporting Period, and the number of new projects signed increased by approximately 20% year-on-year. As at the end of the Reporting Period, the Group had orders totaling approximately RMB3.38 billion. The execution of orders was affected by multiple factors. Investors are advised to exercise caution when dealing in shares of the Company.

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Type of audit opinion

Applicable Not applicable

(II) Financial statements**Consolidated Balance Sheet**

31 March 2024

Prepared by: JOINN Laboratories (China) Co., Ltd.

Unit: RMB Currency: RMB Type of audit: Unaudited

Item	31 March 2024	31 December 2023
Current assets:		
Monetary fund	2,865,314,156.35	2,862,911,984.90
Provision of settlement fund		
Funds lent		
Financial assets held for trading	441,959,028.82	373,354,146.08
Derivative financial assets		
Bills receivables	3,323,300.00	6,873,300.00
Account receivables	189,795,167.61	206,014,475.30
Receivables financing		
Prepayments	100,481,927.64	110,147,213.48
Premium receivables		
Reinsurance account receivables		
Deposit receivables from reinsurance contracts		
Other receivables	17,681,186.33	11,507,653.51
Including: Interest receivables		
Dividend receivables		
Financial assets purchased under agreements to resell		
Inventories	1,694,742,247.60	1,863,081,944.56
Including: Data resources		
Contract assets	102,164,830.33	127,171,761.27
Assets held-for-sale		
Non-current assets due within one year	1,525,775,458.10	1,533,490,014.42
Other current assets	29,926,875.80	27,414,846.59
Total current assets	6,971,164,178.58	7,121,967,340.11

Item	31 March 2024	31 December 2023
Non-current assets:		
Loans and advances to customers		
Debt investment		
Other debt investment		
Long-term receivables		
Long-term equity investments	18,969,964.61	19,528,685.37
Investments in other equity instruments	159,840,000.00	159,840,000.00
Other non-current financial assets	588,130,849.43	587,783,644.59
Investment properties		
Fixed assets	567,767,719.05	583,318,976.70
Construction in progress	366,628,530.59	342,008,170.08
Biological assets for breeding	405,626,508.11	558,873,617.05
Oil and gas assets		
Right-of-use assets	57,252,630.16	63,450,726.95
Intangible assets	288,930,233.19	292,379,829.73
Including: Data resources		
Development expenses		
Including: Data resources		
Goodwill	136,243,271.94	136,007,078.53
Long-term deferred expenditures	72,482,056.66	74,889,044.45
Deferred tax assets	33,431,849.75	28,251,272.62
Other non-current assets	66,786,695.23	58,861,244.29
Total non-current assets	2,762,090,308.72	2,905,192,290.36
Total assets	9,733,254,487.30	10,027,159,630.47
Current liabilities:		
Short-term borrowings		
Borrowings from central bank		
Funds borrowed		
Financial liabilities held for trading		
Derivative financial liabilities		
Bills payables		
Account payables	41,090,088.10	43,323,313.28
Receipts in advance		
Contract liabilities	1,238,607,002.41	1,151,973,539.70

Item	31 March 2024	31 December 2023
Financial assets sold under agreements to repurchase		
Deposits from customers and banks		
Customer deposits for securities trading		
Customer deposits for securities underwriting		
Employee benefit payables	72,971,790.47	106,582,526.14
Tax payables	36,926,218.12	44,600,630.06
Other payables	80,337,535.89	88,992,348.61
Including: Interest payables		
Dividend payables		
Handling charges and commission payable		
Reinsurance account payables		
Liabilities held-for-sale		
Non-current liabilities due within one year	27,963,551.54	27,499,926.74
Other current liabilities	4,667,353.91	4,392,804.11
Total current liabilities	1,502,563,540.44	1,467,365,088.64
Non-current liabilities:		
Deposits for insurance contracts		
Long-term borrowings		
Debtore payables		
Including: Preference shares		
Perpetual bonds		
Lease liabilities	35,532,425.03	41,924,537.74
Long-term payables		
Long-term payroll payables		
Projected liabilities		
Deferred income	71,863,037.27	74,487,463.86
Deferred tax liabilities	129,567,321.33	162,342,125.15
Other non-current liabilities		
Total non-current liabilities	236,962,783.63	278,754,126.75
Total liabilities	1,739,526,324.07	1,746,119,215.39

Item	31 March 2024	31 December 2023
Owners' equity (or shareholders' equity):		
Paid up capital (or share capital)	749,888,699.00	749,888,699.00
Other equity instruments		
Including: Preference shares		
Perpetual bonds		
Capital reserves	5,267,128,243.75	5,267,128,243.75
Less: Treasury shares	161,262,503.48	146,450,061.16
Other comprehensive income	101,381,930.93	100,518,137.39
Special reserve		
Surplus reserve	144,259,244.76	144,259,244.76
General risks reserve		
Retained earnings	1,891,748,985.62	2,163,971,460.61
Total owners' equity (or shareholders' equity) attributable to the parent company	7,993,144,600.58	8,279,315,724.35
Non-controlling interests	583,562.65	1,724,690.73
Total owners' equity (or shareholders' equity)	7,993,728,163.23	8,281,040,415.08
Total liabilities and owners' equity (or shareholders' equity)	9,733,254,487.30	10,027,159,630.47

Legal Representative:
Feng Yuxia

Chief Financial Officer:
Yu Aishui

*Director of the Accounting
Department:*
Yu Aishui

Consolidated Income Statement
January to March 2024

Prepared by: JOINN Laboratories (China) Co., Ltd.

Unit: RMB Currency: RMB Type of audit: Unaudited

Item	First quarter of 2024	First quarter of 2023
I. Total revenue	324,809,103.67	369,386,010.95
Including: Operating Revenue	324,809,103.67	369,386,010.95
Interest income		
Premiums earned		
Handling charges and commission income		
II. Total cost	293,294,646.96	262,811,341.25
Including: Operating Cost	218,156,989.73	178,430,001.04
Interest expenses		
Handling charges and commission expenses		
Payments on surrender		
Net claim expenses		
Net provision for insurance contract reserves		
Policyholder dividend expenses		
Reinsurance costs		
Taxes and surcharges	2,369,721.32	1,665,149.61
Selling expenses	5,850,463.87	5,361,173.05
Administration expenses	71,961,656.69	74,543,757.54
Research and development expenses	22,967,298.39	27,611,585.58
Finance expenses	-28,011,483.04	-24,800,325.57
Including: Interest expense	653,474.98	854,085.47
Interest income	29,068,900.75	30,639,976.24

Item	First quarter of 2024	First quarter of 2023
Add: Other income	6,650,918.69	11,347,382.60
Investment gains ("–" indicating loss)	6,972,038.25	514,120.05
Including: Gains from investment in associates and joint ventures	–558,720.76	–769,932.19
Derecognition of income from financial assets measured at amortised cost		
Exchange gains ("–" indicating loss)		
Gains from net exposure to hedging ("–" indicating loss)		
Gains from changes in fair value ("–" indicating loss)	–310,012,920.11	98,441,604.72
Credit impairment losses ("–" indicating loss)	–1,868,335.27	–2,090,412.59
Assets impairment losses ("–" indicating loss)	–26,264,433.00	–417,677.50
Gains from disposal of assets ("–" indicating loss)		
III. Operating profit ("–" indicating loss)	–293,008,274.73	214,369,686.98
Add: Non-operating income	10,364.83	21,369.30
Less: Non-operating expenses	132,105.74	62,132.34
IV. Profits before income tax ("–" indicating total losses)	–293,130,015.64	214,328,923.94
Less: Income tax expenses	–19,766,412.57	26,618,845.32
V. Net profits ("–" indicating net loss)	–273,363,603.07	187,710,078.62
(I) Classified by the continuity of operation		
1. Net profit from continuing operations ("–" indicating net loss)	–273,363,603.07	187,710,078.62
2. Net profit from discontinued operations ("–" indicating net loss)		
(II) Classified by the ownership		
1. Net profit attributable to equity shareholders of the parent ("–" indicating net loss)	–272,222,474.99	187,759,654.85
2. Profit and loss of non-controlling interests ("–" indicating net loss)	–1,141,128.08	–49,576.23

Item	First quarter of 2024	First quarter of 2023
VI. Other comprehensive income, net of tax	863,793.54	-4,402,644.75
(I) Other comprehensive income attributable to owners of the parent company, net of tax	863,793.54	-4,402,644.75
1. Other comprehensive income that will not be reclassified to profit or loss		
(1) Changes in re-measurement of defined benefit plans		
(2) Other comprehensive income that will not be transferred to profit or loss accounted for using equity method		
(3) Changes in fair value of investments in other equity instruments		
(4) Changes in fair value of the company's own credit risk		
2. Other comprehensive income that will be reclassified to profit or loss	863,793.54	-4,402,644.75
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method		
(2) Changes in fair value of other debt investments		
(3) Financial assets reclassified to other comprehensive income		
(4) Credit impairment allowance of other debt investments		
(5) Cash flow hedging reserve		
(6) Exchange difference on translation of foreign financial statements	863,793.54	-4,402,644.75
(7) Others		
(II) Other comprehensive income attributable to minority shareholders, net of tax		

Item	First quarter of 2024	First quarter of 2023
VII. Total comprehensive income	-272,499,809.53	183,307,433.87
(I) Total comprehensive income attributable to equity shareholders of the parent company	-271,358,681.45	183,357,010.10
(II) Total comprehensive income attributable to non-controlling interests	-1,141,128.08	-49,576.23
VIII. Earnings per share:		
(I) Basic earnings per share (RMB per share)	-0.36	0.25
(II) Diluted earnings per share (RMB per share)	-0.36	0.25

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was RMB0 (corresponding period of the previous year: RMB0).

Legal Representative:
Feng Yuxia

Chief Financial Officer:
Yu Aishui

*Director of the Accounting
Department:*
Yu Aishui

Consolidated Cash Flow Statement
January to March 2024

Prepared by: JOINN Laboratories (China) Co., Ltd.

Unit: RMB Currency: RMB Type of audit: Unaudited

Item	First quarter of 2024	First quarter of 2023
I. Cash flows from operating activities:		
Cash received from the sale of goods and rendering of services	474,100,914.45	613,167,483.43
Net increase in deposits from customers and placements from bank and other financial institutions		
Net increase in borrowings from central bank		
Net increase in borrowings from other financial institutions		
Cash received from premiums of original insurance contracts		
Net cash received from reinsurance operations		
Net increase in policyholders' deposits and investments		
Cash received from interest, handling charges and commission		
Net increase in loans from banks and other financial institutions		
Net increase in capital for repurchase		
Net cash received from securities trading agency services		
Refund of taxes and surcharges		1,348,890.17
Cash received from other operating activities	18,489,046.65	21,309,163.45
Sub-total of cash inflow from operating activities	492,589,961.10	635,825,537.05
Cash paid for goods purchased and service rendered	106,579,918.70	331,661,257.87
Net increase in loans and advances to customers		
Net increase in placements with central bank and other financial institutions		

Item	First quarter of 2024	First quarter of 2023
Cash paid for claims on original insurance contracts		
Net increase in loans to banks and other financial institutions		
Cash paid for interest, handling charges and commission		
Cash paid for policyholders' dividend		
Cash paid to and on behalf employees	197,090,284.39	214,475,730.01
Taxes paid	39,866,650.10	75,888,500.61
Cash paid for other operating activities	29,099,588.60	27,468,232.62
Subtotal of cash outflow from operating activities	372,636,441.79	649,493,721.11
Net cash flow from operating activities	119,953,519.31	-13,668,184.06
II. Cash flow from investing activities:		
Cash received from disposal of investments	90,771,222.22	206,718,985.70
Cash received from returns on investment	11,478,948.50	2,013,580.31
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	3,350.00	4,717.48
Net cash received from disposal of subsidiaries and other business entities		
Cash received from other investing activities	9,200,000.00	13,617,661.10
Sub-total of cash inflow from investing activities	111,453,520.72	222,354,944.59
Cash paid to acquire fixed assets, intangible assets and other long-term assets	59,015,819.37	55,878,731.98
Cash paid to acquire investments	120,000,000.00	60,000,000.00
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other business entities		
Cash paid for other investing activities		
Subtotal of cash outflow from investing activities	179,015,819.37	115,878,731.98
Net cash flow from investing activities	-67,562,298.65	106,476,212.61

Item	First quarter of 2024	First quarter of 2023
III. Cash flow from financing activities:		
Cash received from capital contributions		
Including: Cash received from capital contribution by minority shareholders of subsidiaries		
Cash received from borrowings		
Cash received relating to other financing activities		
Sub-total of cash inflow from financing activities		
Cash repayments of borrowings		861,696.20
Cash payments for distribution of dividends, profits or interest expenses		55,069.95
Including: Dividends and profits paid by subsidiaries to non-controlling interests		
Cash payments relating to other financing activities	37,928,364.49	23,935,585.72
Sub-total of cash outflow from financing activities	37,928,364.49	24,852,351.87
Net cash flow from financing activities	-37,928,364.49	-24,852,351.87
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-2,795,727.79	-6,273,367.27
V. Net increase in cash and cash equivalents	11,667,128.38	61,682,309.41
Add: Cash and cash equivalents at the beginning of the period	2,853,647,027.97	2,899,469,580.53
VI. Cash and cash equivalents at the end of the period	2,865,314,156.35	2,961,151,889.94

Legal Representative:
Feng Yuxia

Chief Financial Officer:
Yu Aishui

Director of the Accounting Department:
Yu Aishui

(III) Adjustments to financial statements at the beginning of the year upon initial adoption of new accounting standards or interpretation of standards since 2024

Applicable Not applicable

This announcement is hereby made.

Board of Directors of JOINN Laboratories (China) Co., Ltd.
29 April 2024